Amyloid diseases of the heart: current and future therapies (Q27023836)

R. L. Comenzo

series ordinal

2

1 reference

language of work or name

1 reference

July 2012

1 reference

QJM: An International Journal of Medicine

published in

1 reference

volume

105

1 reference

page(s)

617-31

1 reference

issue

7

1 reference

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Immunoglobulin free light chain dimers in human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

21 January 2018

Amyloid heart disease

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Diagnosis and management of the cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Managing systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

21 January 2018

How I treat amyloidosis

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Cardiac transplantation for amyloid heart disease: the United Kingdom experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry for heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Antibody-mediated resolution of light chain-associated amyloid deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Liver transplantation in transthyretin-related familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Accelerating restrictive cardiomyopathy after liver transplantation in a patient with familial amyloidotic polyneuropathy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Outcome of liver transplantation for familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Human plasma fibrinogen is synthesized in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Livers from patients with apolipoprotein A-I amyloidosis are not suitable as "domino" donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Natural history and outcome in systemic AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Evaluation of non-synonymous NPPA single nucleotide polymorphisms in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Disturbed secretion of atrial natriuretic peptide in patients with persistent atrial standstill: Endocrinologic silence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Combined heart and liver transplantation for familial amyloidotic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Combined heart and liver transplantation for familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Tabulation of human transthyretin (TTR) variants, 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Solid Organ Transplantation in AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259

Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR259